Table 3.
Urinary recovery (Ae) and renal clerance (ClRen) (mean ± s.d.) of enantiomers of citalopram (CT) and its metabolites desmethylcitalopram (DCT) and didesmethylcitalopram (DDCT) in 18 healthy Swedish volunteers divided into three panels (n = 6 in each panel). Racemic CT was given until steady-state concentration, 10 mg twice daily for 7 days. Urine was collected during a dose interval (0–12 h) after the last dose. NQ, Not quantifiable.
| Total | ClRen, l h−1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ae,% dose | S-CT | R-CT | S-DCT | R-DCT | S-DDCT | R-DDCT | Ae% | S-CT | R-CT | S-DCT | R-DCT | S-DDCT | R-DDCT |
| EMDe/EMMe | 7.2 ± 3.3 | 12.9 ± 5.1 | 6.7 ± 1.6 | 6.7 ± 1.6 | 1.0 ± 0.6 | 2.3 ± 1.3 | 36.8 ± 1.7 | 4.3 ± 1.6 | 4.7 ± 1.6 | 11.1 ± 4.3 | 9.8 ± 3.7 | 10.8 ± 4.0 | 15.5 ± 5.8 |
| PMDe/EMMe | 5.8 ± 1.7 | 14.0 ± 4.6 | 7.1 ± 1.9 | 7.2 ± 2.4 | NQ | NQ | 34.1 ± 1.9 | 4.1 ± 1.3 | 4.7 ± 1.7 | 9.6 ± 2.3 | 9.3 ± 2.3 | NQ | NQ |
| EMDe/PMMe | 10.4 ± 3.5 | 11.7 ± 3.8 | 4.5 ± 1.1 | 4.1 ± 1.1 | 0.9 ± 0.4 | 1.8 ± 0.7 | 33.4 ± 1.8 | 3.9 ± 1.3 | 4.3 ± 1.4 | 8.1 ± 2.4 | 8.1 ± 2.4 | 9.4 ± 3.9 | 12.1 ± 4.4 |
| Kruskal–Wallis | 0.07 | 0.51 | 0.06 | 0.05 | – | – | – | 0.51 | 1.0 | 0.13 | 0.14 | – | – |
| anova, P | |||||||||||||